Evidence map›Paper›PMID 37068140›Full record

ArticleReproduction (Cambridge, England)2023

Oxidative phosphorylation inhibitors inhibit proliferation of endometriosis cells.

Arvinder Kapur, Jose M Ayuso, Shujah Rehman, Santosh Kumari, Mildred Felder, Zach Stenerson, Melisa C Skala, Dave Beebe, Lisa Barroilhet, Manish S Patankar

Open access · greenAbstract read
In one paragraph

Article in Reproduction (Cambridge, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Exploring endometriosis through 3DMaterials today. Bio · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Arvinder KapurDepartment of Obstetrics and Gynecology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Jose M AyusoDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Shujah RehmanMorgridge Institute for Research, Madison, Wisconsin, USA.
Santosh KumariDepartment of Dermatology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Mildred FelderDepartment of Obstetrics and Gynecology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Zach StenersonUniversity of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, USA.
Melisa C SkalaMorgridge Institute for Research, Madison, Wisconsin, USA.
Dave BeebeDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Lisa BarroilhetDepartment of Obstetrics and Gynecology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Manish S PatankarDepartment of Obstetrics and Gynecology, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID 0000-0002-8205-6432
University of Wisconsin–Madison · USMorgridge Institute for Research · USUniversity of Wisconsin Carbone Cancer Center · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
Mechanisms of microenvironment mediated resistance to cancer cell surface targeted therapeuticsUG3CA260692 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI BEEBE, DAVID J, LANG, JOSHUA MICHAEL · 2020 to 2021
$1.6M
Repurposing Atovaquone for Preventing Ovarian Cancer: An Example of Successful Inhibition of Oxidative PhosphorylationR01CA238423 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI BARROILHET, LISA M · 2020 to 2024
$1.5M
Developing non-human primate models for ovarian cancerR21CA234804 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI PATANKAR, MANISH S · 2020 to 2020
$399k
Using a chemical biology approach to develop novel inhibitors of mitochondrial oxidative phosphorylation for the treatment of ovarian cancerI01BX005627 · VA · WM S. MIDDLETON MEMORIAL VETERANS HOSP · PI PATANKAR, MANISH S · 2022 to 2025
–
BLRD VA I01 BX005627NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA238423NCI NIH HHS R21 CA234804NCI NIH HHS UG3 CA260692
6 · The paper itself

Abstract

In brief: Developing novel therapies to cure and manage endometriosis is a major unmet need that will benefit over 180 million women worldwide. Results from the current study suggest that inhibitors of oxidative phosphorylation may serve as novel agents for the treatment of endometriosis. Abstract: Current therapeutic strategies for endometriosis focus on symptom management and are not curative. Here, we provide evidence supporting the inhibition of oxidative phosphorylation (OXPHOS) as a novel treatment strategy for endometriosis. Additionally, we report an organotypic organ-on-a-chip luminal model for endometriosis. The OXPHOS inhibitors, curcumin, plumbagin, and the FDA-approved anti-malarial agent, atovaquone, were tested against the endometriosis cell line, 12Z, in conventional as well as the new organotypic model. The results suggest that all three compounds inhibit proliferation and cause cell death of the endometriotic cells by inhibiting OXPHOS and causing an increase in intracellular oxygen radicals. The oxidative stress mediated by curcumin, plumbagin, and atovaquone causes DNA double-strand breaks as indicated by the elevation of phospho-γH2Ax. Mitochondrial energetics shows a significant decrease in oxygen consumption in 12Z cells. These experiments also highlight differences in the mechanism of action as curcumin and plumbagin inhibit complex I whereas atovaquone blocks complexes I, II, and III. Real-time assessment of cells in the lumen model showed inhibition of migration in response to the test compounds. Additionally, using two-photon lifetime imaging, we demonstrate that the 12Z cells in the lumen show decreased redox ratio (NAD(P)H/FAD) and lower fluorescence lifetime of NAD(P)H in the treated cells confirming major metabolic changes in response to inhibition of mitochondrial electron transport. The robust chemotoxic responses observed with atovaquone suggest that this anti-malarial agent may be repurposed for the effective treatment of endometriosis.

Indexed as

AntimalarialsAntineoplastic AgentsCurcuminEndometriosisAtovaquoneCell ProliferationFemaleHumansNADNaphthoquinonesOxidative PhosphorylationAntimalarialsAntineoplastic AgentsAtovaquoneCurcuminNADNaphthoquinonesplumbagin

Identifiers

PMID37068140
PMCPMC10601975
OpenAlexW4366085572

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.